38 citations
,
March 2015 in “Journal of controlled release” IMSG nanoparticles improve vaccine delivery and immune response through hair follicles.
1 citations
,
April 2017 in “Journal of Dermatology and Dermatologic Surgery” IVIG therapy was linked to hair regrowth in two patients with hair loss, but it's not recommended due to its risks and costs.
January 2026 in “Journal of Investigative Dermatology” 3D imaging effectively tracks skin changes in vitiligo treatment.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
August 2019 in “Reactions Weekly” Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
2 citations
,
December 2024 in “International Journal of Rheumatic Diseases” Ocrelizumab may cause total body hair loss in some patients.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
June 2026 in “Frontiers in Oncology” Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
February 2026 in “Indian Dermatology Online Journal” Tofacitinib significantly improved skin and hair conditions without side effects.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
142 citations
,
November 2009 in “BMC Complementary and Alternative Medicine” Tridax procumbens significantly lowers blood sugar in diabetic rats.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
3 citations
,
January 2016 in “Case reports in dermatological medicine” An 80-year-old man grew extra hair on his forearms after starting Alzheimer's medication rivastigmine.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
3 citations
,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
15 citations
,
January 2019 in “Journal of the Formosan Medical Association” Adalimumab helped control a child's severe eye disease when other treatments failed.